TriangleNCT00238121 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Month
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 5 years
What was measured
Defined as the time from the first day of therapy to the date of death. If the patient was lost to follow-up, survival was censored on the last date the patient was known to be alive.
Groups in this outcome
Carcinoma
Patients with advanced uterine carcinoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Carcinosarcoma
Patients with advanced uterine carcinosarcoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Carcinoma | 38 |
| Carcinosarcoma | 14 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Carcinoma | 11.4 | Not reported | 6.9 | 17.7 | Not reported |
| Carcinosarcoma | 5 | Not reported | 1.4 | 14 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.9
- upper Limit
- 17.7
- value
- 11.4
- group Id
- OG001
- lower Limit
- 1.4
- upper Limit
- 14
- value
- 5
- denoms
- counts
- group Id
- OG000
- value
- 38
- group Id
- OG001
- value
- 14
- units
- Participants
- description
- Defined as the time from the first day of therapy to the date of death. If the patient was lost to follow-up, survival was censored on the last date the patient was known to be alive.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients with advanced uterine carcinoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Carcinoma
- description
- Patients with advanced uterine carcinosarcoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG001
- title
- Carcinosarcoma
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- Month
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice